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Abstract
Background: All-cause mortality risk and causes of death in bronchiectasis patients have not been fully investigated.
The aim of this study was to compare the mortality risk and causes of death between individuals with bronchiectasis
and those without bronchiectasis.
Methods: Patients with or without bronchiectasis determined based on chest computed tomography (CT) at one
centre between 2005 and 2016 were enrolled. Among the patients without bronchiectasis, a control group was
selected after applying additional exclusion criteria. We compared the mortality risk and causes of death between the
bronchiectasis and control groups without lung disease. Subgroup analyses were also performed according to
identification of Pseudomonas or non-tuberculous mycobacteria, airflow limitation, and smoking status.
Results: Of the total 217,702 patients who underwent chest CT, 18,134 bronchiectasis patients and 90,313 non-
bronchiectasis patients were included. The all-cause mortality rate in the bronchiectasis group was 1608.8 per 100,000
person-years (95% confidence interval (CI), 1531.5–1690.0), which was higher than that in the control group (133.5 per
100,000 person-years; 95% CI, 124.1–143.8; P < 0.001). The bronchiectasis group had higher all-cause (adjusted hazard
ratio (aHR), 1.26; 95% CI, 1.09–1.47), respiratory (aHR, 3.49; 95% CI, 2.21–5.51), and lung cancer-related (aHR, 3.48; 95% CI,
2.33–5.22) mortality risks than the control group. In subgroup analysis, patients with airflow limitation and ever smokers
showed higher all-cause mortality risk among bronchiectasis patients. Therefore, we observed significant interrelation
between bronchiectasis and smoking, concerning the risks of all-cause mortality (P for multiplicative interaction, 0.030,
RERI, 0.432; 95% CI, 0.097–0.769) and lung cancer-related mortality (RERI, 8.68; 95% CI, 1.631–15.736).
Conclusion: Individuals with bronchiectasis had a higher risk of all-cause, respiratory, and lung cancer-related mortality
compared to control group. The risk of all-cause mortality was more prominent in those with airflow limitation and in
ever smokers.
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Background
Non-cystic fibrosis bronchiectasis (hereafter referred to
as bronchiectasis) is characterised by the irreversible
dilation of the bronchial lumen caused by recurrent or
chronic infection and inflammation, which is not related
to cystic fibrosis, and clinically it causes chronic cough,
sputum, and respiratory infection [1]. Not only is bron-
chiectasis a chronic respiratory disease with substantial
disease burden worldwide, but it is also associated with
significant morbidity and hospitalization [2, 3]. Accord-
ing to the data from health-care claims in the United
States, the prevalence of bronchiectasis was over 500 per
100,000 persons in 2000 and over 800 per 100,000
persons in 2007 which showed a continuous increase
over time [3, 4]. Moreover, the increased demand for
medical resources for patients with bronchiectasis
cannot be ignored since annually, patients with bronchi-
ectasis demonstrated significantly increased medical
costs, outpatient visits, and a higher admission rate than
normal populations [5, 6]. However, bronchiectasis has
been an underestimated disease in spite of its rampancy
and the increasing economic burden of the disease as
well as its considerable morbidity and mortality [3–10].
Although there have been several studies reporting mor-
tality in patients with bronchiectasis, several issues re-
main unaddressed. Previous studies have reported on
the death rates of patients with bronchiectasis, but those
had a wide range (10–42% at 4–5 years and 22–30% at
34–35 years) [9, 11–14]. Furthermore, it has not been
verified if bronchiectasis leads to a higher risk for early
death. Previous studies have not included control groups
to compare the mortality risk to those with bronchiec-
tasis. Moreover, until now there has been a lack of stud-
ies regarding cause of death in patients with
bronchiectasis, and no large-scale study has been con-
ducted in Asia, where bronchiectasis is more common
than in western countries.
The main objective of the present study was to investi-
gate all-cause mortality risk and causes of death in pa-
tients with bronchiectasis compared with those in the
non-bronchiectatic control group without lung disease.
We also attempted to identify higher mortality risk sub-
groups among those with bronchiectasis.
Methods
Study design and participants
This retrospective cohort study included participants
aged ≥20 years who underwent chest computed tomog-
raphy (CT) at the Seoul National University Hospital
between January 1, 2005 and December 31, 2016. The
diagnosis of bronchiectasis was determined based on the
CT report, which was assessed by radiologists. Index
date was the time when these patients underwent chest
CT. We excluded those regarded to have previously
undergone lung resection surgery (such as pneumonec-
tomy, lobectomy, segmentectomy, wedge resection,
metastasectomy, or video-assisted thoracoscopic surgery
[VATS] lung biopsy) on the chest CT or those with sig-
nificant non-respiratory (malignancy, liver cirrhosis,
chronic kidney disease, heart failure, acquired immune
deficiency syndrome, connective tissue disease, organ
transplantation) or respiratory diseases (interstitial lung
disease, pneumoconiosis, pleurisy, empyema, sarcoidosis,
kyphosis, or tuberculous-destroyed lung) which may
affect the prognosis. The identification of comorbidities
or exclusion criteria was based on ICD-10 codes regis-
tered within two years before and after the index date.
Those with traction bronchiectasis were also excluded.
To ensure appropriate selection of individuals in the
non-bronchiectasis control group, we applied the follow-
ing additional exclusion criteria: 1) isolation of nontu-
berculous mycobacteria (NTM) from a respiratory
specimen at least once; 2) a forced expiratory volume in
one second (FEV1)/forced vital capacity (FVC) ratio < 0.7
or FEV1 < 80% predicted value; or 3) other abnormalities
on CT such as pneumonia, active pulmonary tubercu-
losis, pneumothorax, pleural effusion, pericardial effu-
sion, pulmonary embolism, embolization in coronary
artery, aorta or bronchial artery, pleural calcification, or
haemoptysis. In the bronchiectasis group, patients were
divided into two categories according to the isolation of
NTM, the isolation of Pseudomonas, smoking status,
and airflow limitation defined as a FEV1/FVC of less
than 0.7. During the study period, patients with any evi-
dence of NTM or Pseudomonas were classified into
NTM or Pseudomonas subgroups. This study was ap-
proved by the Institutional Review Board of the Seoul
National University Hospital (IRB No. H-1607-037-774)
and conformed to the tenets of the Declaration of
Helsinki. Informed consent was waived due to its retro-
spective nature.
Statistical analysis
Baseline demographic data, comorbidities, smoking his-
tory, sputum culture results, and lung function results
were collected by using data based on electronic medical
records (EMRs). Student’s t-test or analysis of variance
was used for between-group comparisons of demograph-
ics involving continuous variables, and the chi-square
test for those involving categorical variables. Mortality
and cause of death before 2016 December 31 was
determined based on the mortality data from the Korean
National Statistical Office. Cox proportional hazard
regression analysis was used to present adjusted hazard
ratios (aHR) and their 95% confidence intervals (CI). In
addition, the proportion of mortality risks attributable to
risk factors (population attributable risk fraction, PAF)
and their 95% CIs were estimated. P-values for
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multiplicative interactions, as well as relative excess risk
due to interaction (RERI) and attributable proportion
(AP) for additive interactions were evaluated, along with
their 95% CIs. P-values less than 0.05 were considered
statistically significant. Data analyses were conducted
using Stata14.2 (Stata Corp, College station, Texas).
Results
Baseline characteristics
We initially identified 217,702 individuals who under-
went a chest CT scan during the study period. Among
those, 18,134 participants with bronchiectasis and 90,
313 non-bronchiectatic control participants were in-
cluded (Fig. 1). The baseline demographics of the sub-
jects are shown in Table 1. The bronchiectasis group
was older, had more females, and had a high proportion
of comorbidities and poorer lung function.
Mortality risk
In total, 1653 (9.12%) deaths in the bronchiectasis group
and 714 (0.79%) deaths in the control group were ob-
served during 5.9 ± 3.4 and 5.4 ± 3.5 years of mean follow
up period, respectively. The all-cause mortality rate in
the bronchiectasis group was 1608.8 per 100,000 person-
years (95% CI, 1531.5–1690.0) which was higher than
that of the control group (133.5 per 100,000 person-
years; 95% CI, 124.1–143.8) (P < 0.001) (Fig. 2). Multivar-
iable cox proportional hazard regression showed that
bronchiectasis remained independently associated with a
higher all-cause mortality risk (aHR, 1.22; 95% CI, 1.02–
1.46) compared with the control group even after
Fig. 1 Flowchart for the study population






Age, years 51.5 ± 11.9 59.6 ± 11.7 < 0.001
Male 52,631 (58.3) 8654 (47.7) < 0.001
BMI, kg/m2 23.8 ± 3.1 22.7 ± 3.3 < 0.001
Smoking < 0.001
Never 15,931 (17.6) 5020 (27.7)
Ever 10,264 (11.4) 2859 (15.8)
Comorbidities
Hypertension 9496 (10.5) 2194 (12.1) < 0.001
Diabetes 6249 (6.9) 1552 (8.6) < 0.001
Dyslipidaemia 13,707 (15.2) 2269 (12.5) < 0.001
COPD 1882 (2.1) 16,498 (9.0) < 0.001
Asthma 2372 (2.6) 1445 (8.0) < 0.001
Baseline PFT, n 60,854 10,279
FEV1 (L) 3.1 ± 0.7 2.3 ± 0.8 < 0.001
FEV1 (% predicted) 98 ± 11 92 ± 16 < 0.001
FVC (L) 3.8 ± 0.9 3.1 ± 0.9 < 0.001
FVC (% predicted) 98 ± 11 92 ± 16 < 0.001
FEV1: FVC ratio (%) 81 ± 5 74 ± 12 < 0.001
Categorical variables are expressed as number (%); continuous variables are
expressed as mean +/− standard deviation.
BMI body mass index, COPD chronic obstructive pulmonary disease, FVC
functional vital capacity, FEV1 forced expiratory volume in 1 s, PFT pulmonary
function test
Sin et al. Respiratory Research          (2019) 20:271 Page 3 of 9
adjustment for age, sex, BMI, smoking history, presence
of diabetes mellitus, hypertension, and dyslipidaemia,
and baseline FEV1(pred. %) (Table 2). In addition, bron-
chiectasis and smoking per se were accountable for 9.3%
(population attributable fraction (PAF), 0.093; 95% CI,
0.012–0.167) and 9.2% (PAF, 0.092; 95% CI, 0.029–
0.151) of all-cause mortality, respectively. Among partic-
ipants with bronchiectasis, smoking was associated with
14.0% (PAF, 0.140; 95% CI 0.042–0.228) of all-cause
mortality, while in the control group, the percentage
attributed to smoking was 5.7% (PAF, 0.057; 95% CI, −
0.025-0.0133). We found multiplicative (P for inter-
action, 0.030) and additive interaction (RERI, 0.432; 95%
CI, 0.097–0.769; AP, 0.274, 95% CI, 0.080–0.469) be-
tween the two factors, regarding the risk of all-cause
mortality. Patients with both bronchiectasis and smoking
history had the highest risk of all-cause mortality among
four subgroups, categorized according to bronchiectasis
and smoking history (aHRs on all-cause mortality (95%
CI); 1.07 (0.86–1.34), 1.07 (0.87–1.32), 1.58 (1.25–1.99)
for ever-smokers in the control group, never-smoker
bronchiectasis patients and ever-smoker bronchiectasis
patients, respectively) (Additional file 3).
Causes of death
The major causes of death in the bronchiectasis group
were malignancy (31.2%), respiratory related (30.6%),
neurological (9.0%), and cardiovascular death (7.1%). In
the control group, malignancy (52.8%), cardiovascular
(9.7%), neurological (9.2%), and suicide (9.1%) were
major causes of death, in that order. Respiratory related
deaths made up a small percentage (4.9%) of the total
Fig. 2 Bronchiectasis increased risk of all-cause mortality in comparison with the control group
Table 2 Bronchiectasis is an independent risk factor of
increased all-cause mortality risk. (multivariable cox proportional
hazard regression analysis)
aHRa 95% CI P-value
Age, year 1.09 1.08–1.10 < 0.001
BMI, kg/m2 0.90 0.88–0.92 < 0.001
Female 0.79 0.67–0.94 0.008
Ever smoker 1.27 1.08–1.49 0.004
Hypertension 0.85 0.70–1.02 0.085
Diabetes 1.16 0.95–1.40 0.145
Dyslipidaemia 0.35 0.27–0.45 < 0.001
FEV1, % pred. 0.98 0.98–0.99 < 0.001
Bronchiectasis 1.22 1.02–1.46 0.028
aAdjusted by Age, BMI, sex, smoking status, hypertension, diabetes,
dyslipidaemia, FEV1 (% pred.), bronchiectasis
CI confidence interval, BMI body mass index, COPD chronic obstructive
pulmonary disease, FVC functional vital capacity, FEV1 forced expiratory
volume in 1 s
Table 3 Causes of death in the control group versus the
bronchiectasis group




Respiratory 35 (4.9) 505 (30.6)
All cancer 377 (52.8) 515 (31.2)
Lung cancer 52 (7.3) 205 (12.4)
Other cancer 325 (45.5) 310 (18.8)
Neurologic 66 (9.2) 148 (9.0)
Cardiologic 69 (9.7) 118 (7.1)
Trauma 40 (5.6) 46 (2.8)
Suicide 65 (9.1) 39 (2.4)
Others 62 (8.7) 282 (17.1)
Total 714 1653
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deaths in the control group (Table 3). Cox regression
analysis showed bronchiectasis was significantly associ-
ated with increased respiratory death (aHR, 3.49; 95%;
CI, 2.21–5.51) and lung cancer-related death (aHR, 3.36;
95% CI, 2.18–5.18) (Fig. 3). An additive interaction
(RERI, 8.68, 95% CI, 1.631–15.736; AP, 0.586, 95% CI,
0.398–0.775) was observed between bronchiectasis and
smoking, concerning the risk of lung cancer-related
mortality. Bronchiectasis was not significantly related to
other causes except for other cancer-related deaths com-
pared with the control group.
Risk factor of all-cause mortality in bronchiectasis
Among 6957 bronchiectasis patients whose respiratory
specimen was tested for acid-fast bacteria (AFB) at least
once during the study period, NTM was isolated in 1740
(25%). Additionally, among 4000 bronchiectasis patients
whose respiratory specimen was tested for bacteria at
least once during the study period, Pseudomonas was
isolated in 378 (9.5%). Among patients with available
lung function data, 2493 (24.3%) exhibited airflow limita-
tions and among patients with available smoking history,
2859 (36.3%) were ever-smokers. According to multivari-
ate Cox regression analysis, which was performed to
evaluate the factors related to increased mortality in pa-
tients with bronchiectasis, airflow limitation and a his-
tory of smoking were significantly associated with
increased mortality (aHR, 1.39; 95% CI, 1.15–1.67; aHR,
1.39; 95% CI, 1.11–1.75) (Fig. 4, Additional file 1 and
Additional file 2).
Fig. 3 Bronchiectasis increased risk of respiratory related death and lung cancer-related death compared with the control group. a Comparision
of respiratory related mortality between bronchiectasis patients and control population b Comparison of lung cancer related mortality between
bronchiectasis patients and control population
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Discussion
The principal finding of the current study was that pa-
tients with bronchiectasis showed an increased risk of
all-cause death, respiratory related death, and lung
cancer-related death compared to control population
without lung disease. Furthermore, all-cause mortality
was higher in those with airflow limitation and in ever
smokers among bronchiectasis patients. We also
observed significant interactions between bronchiectasis
and smoking regarding the risk of mortality.
The strengths of the current study are as follows. This
was the first study to evaluate the association between
bronchiectasis with increased mortality related to re-
spiratory and lung cancer compared with a control
population. In addition, to our knowledge, the present
study has analysed the largest population ever, including
Fig. 4 All-cause mortality risk according to additional risk factors. a Comparison of all-cause mortality risk between never smoker bronchiectasis
patients versus ever smoker bronchiectasis patients b Comparision of all-cause mortality risk between bronchiectasis patients with airflow
limitation versus bronchiectasis patients without airflow limitation
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108,447 persons. Furthermore, there has not been a
study about mortality and causes of death in Asian bron-
chiectasis patients completed previously.
Prior to our study, several studies investigated the
mortality of bronchiectasis patients. However, there is a
lack of consistency in the mortality of patients with
bronchiectasis [9, 11–14]. The current study included a
large number of bronchiectasis patients, with 9.12%
mortality during the 5.8 ± 3.4 years of mean follow up
period. This result is in line with previous studies,
though slightly lower. We selected bronchiectasis pa-
tients by chest CT which was performed for various pur-
poses, contrary to other studies which had enrolled
patients according to the ICD code or the diagnosis
from the respiratory clinic [9, 10, 12, 15, 16]. Therefore,
our inclusion criteria may have enabled us to further
characterise the natural course of bronchiectasis pa-
tients, even for those with mild symptoms, who rarely
visit the respiratory clinics of tertiary hospitals. Further-
more, patients with milder disease, due to the strict in-
clusion criteria not replicated in other studies, may have
influenced the results. In fact, the baseline lung function
of patients in the current study was higher than those in
previous studies; additionally, other studies did not use
exclusion criteria with regard to comorbidities [9–12].
Another possible explanation is that there has been a
lack of studies analysing Asian bronchiectasis patients,
and hence, this result may represent the characteristics
of the Asian population. Nevertheless, further research is
needed.
The present study showed that the all-cause mor-
tality risk of the bronchiectasis group was signifi-
cantly higher than that of the control group. In
total, 1475.3 more deaths per 100,000 person-years
were observed than in the control group. Addition-
ally, we showed the substantial attribution of mortal-
ity to bronchiectasis (PAF, 9.3%), which is
comparable to the percentage attributed to smoking
(PAF, 9.2%). In our study, respiratory related death
could be one major cause that is responsible for this
excess mortality risk. Cole’s vicious cycle model [17]
is the most generally accepted concept in the patho-
genesis of bronchiectasis. According to Cole’s vicious
cycle, structural abnormalities, chronic inflammation,
and recurrent infections continuously cause respira-
tory infections, acute exacerbation, and airflow limi-
tation in patients throughout their lifetime, which
induces premature death associated with respiratory
causes [1, 18]. In fact, respiratory related deaths have
been known to be a major cause of death in bron-
chiectasis [9, 19, 20]. In addition, to our knowledge,
we reported here for the first time the higher risk of
lung cancer-related mortality in those with bronchi-
ectasis even after adjustment of smoking history,
although there are several studies that have investi-
gated the association of bronchiectasis with the inci-
dence of lung cancer in Asian populations [21, 22].
Chronic inflammation and recurrent infections,
which are generally accepted mechanisms for cancer
development [23, 24], may contribute to the develop-
ment of lung cancer in bronchiectasis patients; how-
ever, the exact biological mechanism needs further
clarification. Interestingly, we found a statistically
significant interaction between bronchiectasis and
smoking, the well-known risk factor for lung cancer
[25], concerning the risk of lung cancer-related mor-
tality. Ever-smoker bronchiectasis patients exhibited
the highest risk for lung cancer-related mortality.
This interaction has not been reported before; how-
ever, further studies are needed to validate this find-
ing, and reports related to the underlying
mechanism are expected.
In previous studies, some factors associated with in-
creased mortality or poor prognoses were identified in
patients with bronchiectasis. Older age [9, 12, 13, 26],
male [12, 20], smoking history [9], low BMI [13], isola-
tion of Pseudomonas [12, 27, 28], and lung function
measurements representing airflow limitation [12, 14]
are some factors. Among those, we evaluated the associ-
ation of mortality with factors such as airflow limitation
(FEV1/FVC < 0.7), smoking history, and the isolation of
NTM or Pseudomonas in a respiratory specimen. All
four factors were significantly associated with increased
mortality in patients with bronchiectasis. However, only
airflow limitation and smoking history remained as
significant factors and were associated with increased
mortality in the multivariate analysis. Contrary to the
considerable amount of data available from cystic
fibrosis bronchiectasis patients, data from patients with
non-cystic fibrosis bronchiectasis related to colonization
by Pseudomonas is limited. It has been known that
colonization by Pseudomonas is associated with an in-
creased risk of mortality in cystic fibrosis bronchiectasis
patients [29–31]. However, there are contradictory data
in non-cystic fibrosis bronchiectasis patients [9, 10, 12,
15, 28]. Additionally, although the isolation of NTM in a
respiratory specimen is not unusual [32, 33], its impact
on mortality of NTM isolation in non-cystic fibrosis
bronchiectasis patients remains unknown. Here, the re-
sults of the multivariable cox regression analysis adjusted
for age, sex, BMI, and baseline FEV1 suggest that
colonization by Pseudomonas (aHR, 1.04; 95% CI, 0.74–
1.45) or NTM (aHR, 0.83; 95% CI, 0.64–1.08) may not
be an independent risk factor related to the increased
risk of mortality in non-cystic fibrosis bronchiectasis pa-
tients. However, in our study, sputum collection for
Pseudomonas and NTM culture was conducted in only
22.1 and 38.4% of the participants, respectively. This
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should be addressed since it leads to a limited interpret-
ation of the results.
We acknowledge several limitations in this study.
Firstly, the control group in the current study was
from hospital patients and not community controls.
Hospital controls are more likely to have health re-
lated problems [34, 35] which could attenuate the dif-
ference in mortality risk between the control and
patient groups. However, because community controls
rarely undergo chest CT, which is the gold standard
of diagnosis for bronchiectasis [36], we selected hos-
pital controls. To address this limitation, we excluded
patients with not only significant respiratory and non-
respiratory comorbidities, but also used additional
exclusion criteria. Furthermore, we adjusted various
covariates including age, BMI, sex, smoking history,
comorbidities, and baseline lung function to minimize
bias.
Conclusion
In conclusion, the current study showed that bronchiec-
tasis is significantly associated with an increased risk of
all-cause mortality, respiratory death, and lung cancer-
related death compared with control population without
lung disease. Physicians should pay more attention to
those with airflow limitations and to smokers among
bronchiectasis patients.
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